MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2024 International Congress

    A Preliminary Report on the Clinical Profile of People with PD at an Outpatient Clinic in Malawi

    M. Gwedela, T. Phiri (Blantyre, Malawi)

    Objective: The objective of the study is to analyze the clinical and socio-demographic characteristics of people with Parkinson`s (PwP) attending the adult neurology outpatient clinic…
  • 2024 International Congress

    Genetic Variants and Levodopa Response in Parkinson’s Disease: Insights from MAO-B and DAT1 Polymorphisms

    S. Sarkar, A. Biswas, S. Ansari, S. Sengupta, S. Choudhury, R. Banerjee, S. Chatterjee, S. Dey, H. Kumar (Kolkata, India)

    Objective: This study aimed to find the association of genetic variations between Parkinson’s disease (PD) patients with and without levodopa-induced dyskinesia (LID). we intended to…
  • 2024 International Congress

    24 Hour Maxillofacial Administration of Levodopa in a Parkinsons Patient -An Alternative Route of Administration in Parkinsons Disease

    S. Thirunavukarasu, B. Ramanan, V. Varadharaj, TS. Suresh, KV. Verma, HAJ. Janardhanan, AUR. Ur (PUDUCHERRY, India)

    Objective: To assess tolerability, feasibility, safety and to assess outcome measures clinically as well as by serum levels over 24 hours, using the alternative maxillofacial…
  • 2024 International Congress

    Efficacy and Safety of Controlled-Release Levodopa in Parkinson’s Disease: a Systematic Review and Meta-Analysis

    G. Bolner, Y. Rossi, E. de Almeida, F. de Oliveira, V. Müller, L. Barbosa Lima, A. Rossato, G. Guindani Maia, A. Hilbig (Porto Alegre, Brazil)

    Objective: To evaluate the efficacy and safety of controlled-release levodopa (CRLD) compared with standard release levodopa (SRLD) in patients with Parkinson’s Disease (PD) and motor…
  • 2024 International Congress

    Free-Viewing Eye Tracking and the Effect of Levodopa in Parkinson’s Disease

    A. Gallagher, H. Elliott, J. Inocentes, C. O'Keeffe, B. Coe, D. Brien, B. White, H. Riek, R. Walsh, T. Lynch, R. Reilly, D. Munoz, C. Fearon (Dublin 7, Ireland)

    Objective: The objective of our study is to determine whether differences in oculomotor function and blink rate correlate to the off-and on- medication state in a cohort of…
  • 2024 International Congress

    Long-Term Safety and Efficacy of Foscarbidopa/Foslevodopa in Patients with Advanced Parkinson’s Disease: Results From an Ongoing Phase 3 Open-Label Extension with Up to 1 Year Follow-Up

    R. Hauser, V. Fung, T. Kimber, K. Klos, M. Facheris, A. Jeong, J. Jia, A. Spiegel, M. Soileau (Tampa, USA)

    Objective: Evaluate long-term safety and efficacy of foslevodopa/foscarbidopa (LDp/CDp) among people with advanced Parkinson’s disease (aPD). Background: As aPD progresses, erratic gastric emptying and pulsatile…
  • 2024 International Congress

    Real-World Multicenter Analysis of Levodopa Equivalent Daily Dosage Algorithms- Capturing Geographical and Demographic Disparities in Parkinson’s Disease Therapy Spanning Six Countries and Two Continents

    P. Kukkle, L. Kalia, A. Habib, P. Jagota, R. Ojha, R. Kandadai, S. Desai, M. Caldera, D. Sirisena, D. Garg, T. Mestre, R. Neupane, S. Maytharakcheep, K. Sanyawut, R. Borgohain (Bangalore, India)

    Objective: To assess the influence of updated Levodopa Equivalent Daily Dosage (LEDD) conversion factors in capturing the newer therapies in Parkinson’s Disease (PD) and therapy…
  • 2024 International Congress

    Preventing Medication Errors for Hospitalized People with Parkinson’s Disease – Results of Six Months of Proactive Intervention

    C. Piccinin, J. Yu, A. Brooks, V. Stepanyants, P. Clark, S. Shaffer, B. Sokola, K. Lewin, C. Sonneborn, O. Hogue, S. Sperling, H. Fernandez, W. Walter (Cleveland, USA)

    Objective: To determine whether a Parkinson’s disease (PD) Inpatient Program will prevent medication errors and ultimately improve the safety and quality of care for hospitalized…
  • 2024 International Congress

    A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease

    Y. Tan, Q. Wei, P. Xu, E. Tao, L. Wang, C. Cattaneo, H. Shang, S. Chen (Shanghai, China)

    Objective: To compare  efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…
  • 2024 International Congress

    Combining Carbidopa/levodopa Extended-release Capsules and Immediate-release Tablets – Crucial Factors of This Economical Prescription

    Y. Tai, S. Hsu, H. Kuo (Kaohsiung City, Taiwan)

    Objective: We introduced a new way of prescribing carbidopa/levodopa extended-release (ER) capsule – combining use of immediate-release (IR) tablets. This retrospective clinical study was designed…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24752 (not found)
  • An atypical and interesting feature of Parkinson´s disease
  • Fasciculations from a cholinesterase inhibitor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley